NCT01381107View on ClinicalTrials.gov

ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Major Depressive Disorder
Interventions
DRUG

ALKS 5461

Sublingual administration once daily for 7 consecutive days.

DRUG

Placebo

Sublingual administration once daily for 7 consecutive days.

Trial Locations (2)

30328

Comprehensive NeuroScience, Inc., Atlanta

33716

Comprehensive NeuroScience, Inc., St. Petersburg

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT01381107 - ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD | Biotech Hunter | Biotech Hunter